California Governor rejects Biosimilars Bill

14 October 2013

The Governor of the US state of California, Jerry Brown, on Saturday (October 11) vetoed proposed legislation on the dispensing of biosimilar drugs, copy versions of high-priced biological medicines, to patients in the state.

Senate Bill 598, authored by Senator Jerry Hill (Democrat, San Mateo), would have allowed pharmacists to substitute a new class of biologic medicines, or “biosimilars,” for a brand biologic when the biosimilar is deemed interchangeable by the Food and Drug Administration and require that a patient’s physician is notified which biologic medicine was dispensed (The Pharma Letter August 5).

While the majority of biologic medicines are dispensed and administered by physicians, a small percentage of patients receive them through pharmacies. In a veto message on Saturday, Gov Brown said the bill was premature because federal regulators had not even determined the standards governing the cheaper drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biosimilars